Although ASXL1 and DNMT3A mutations were frequent in AA, MDS and AML, there is a substantial underrepresentation of mutations in splicing-factor genes, JAK2, and TP53 in AA compared with MDS and AML, reflecting the difference in the mechanism of clonal selection between both diseases and mutations. This evidence concerns the gene JAK2 and acute myeloid leukemia.